Evotec's 16-year CSO tenure ends as Evotec stock sits 61.92 percent below high

Published on 10/12/2026 at 09:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evotec's CSO stepped down on September 30, 2026 after 16 years. Evotec stock costs EUR 2.78 on October 12, 2026 versus EUR 2.77.

Key points in brief

Evotec's chief scientific officer stepped down after 16 years, with a successor search under way.
Evotec stock was at EUR 2.78 at Lang & Schwarz on October 12, 2026, 0.43 percent above the October 9 Xetra close.
The stock stood 61.92 percent below its EUR 7.30 52-week high and 2.58 percent above its EUR 2.71 low.
Evotec's next confirmed reporting date is November 5, 2026, for its third-quarter report.

Aquarellillustration der Hamburger Skyline mit Elbphilharmonie und Hafen bei Sonnenuntergang — Aquarellmalerei der Hamburger Skyline repräsentiert den Firmensitz von Evotec SE, ISIN DE0005664809, mit Elbphilharmonie, Illustration mit AI erstellt.

Evotec (ISIN DE0005664809) was trading at EUR 2.78 at Lang & Schwarz on October 12, 2026 at 9:08 a.m. CEST, 0.43 percent above the Xetra close of October 9, 2026 at EUR 2.77. PR Newswire reported on September 29, 2026 that Chief Scientific Officer Cord Dohrmann would step down effective September 30 after 16 years at the company.

Three dated milestones

On August 13, 2026, Evotec published its half-year financial report, a reporting milestone that preceded the management changes. On September 16, 2026, the company highlighted its fireside chat at the Morgan Stanley Annual Healthcare Conference on its Evotec investor-relations page. On September 29, 2026, the company announced the CSO transition, with the effective date set for September 30.

What does the transition change?

PR Newswire said Dohrmann had served as chief scientific officer and a Management Board member since 2010, while the search for a successor was under way. The release also described the scientific infrastructure built during his tenure across iPSC-based technologies and omics as an essential component of future growth and profitability.

For investors, the transition creates a measurable governance checkpoint: the company must replace a scientific leader with 16 years of institutional experience while maintaining its platform strategy. The release identified Evotec's work across small molecules, biologics, cell therapies and related modalities, and said the company works with more than 800 biotech companies and all Top 20 pharmaceutical companies.

Stock remains near its yearly low

At EUR 2.78, Evotec stock was 61.92 percent below its 52-week high of EUR 7.30 and 2.58 percent above its 52-week low of EUR 2.71 on October 12, 2026. The market capitalization was EUR 491.6 million as of October 9, 2026, while the Xetra quotation closed at EUR 2.77 on that date.

Berenberg kept its Hold rating and EUR 3.60 price target on September 25, 2026. That target is 29.45 percent above the Lang & Schwarz price, but the analyst cited commercial realignment, delayed milestones and limited visibility on revenue development.

Next reporting date is November 5

comdirect lists November 5, 2026 as Evotec's confirmed date for reporting third-quarter 2026 results. That date gives the management transition a clear near-term checkpoint for operating updates and any successor announcement.

Evotec stock at EUR 2.78

Evotec was trading at EUR 2.78 at Lang & Schwarz on October 12, 2026 at 9:08 a.m. CEST, plus 0.43 percent versus the Xetra close of October 9, 2026 at EUR 2.77. The further course of trading is shown by the continuously updated real-time quote of Evotec stock.